Skip to main content

Table 2 Laboratory findings at baseline and after TACE

From: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization

Laboratory findings

Baseline, Mean ± SD

Post-TACE, Mean ± SD

p-value

Total bilirubin (mg/dL)

1.03 ± 0.61

1.17 ± 0.86

0.027*

AST (U/L)

77.20 ± 51.65

73.69 ± 57.05

0.59

ALT (U/L)

56.21 ± 38.35

52.48 ± 43.95

0.300

Albumin (g/dL)

3.50 ± 0.57

3.20 ± 0.56

<0.001*

INR

1.16 ± 0.13

1.20 ± 0.13

<0.001*

Platelet (× 103/µL)

167.46 ± 107.53

169.58 ± 116.82

0.62

Creatinine (mg/dL)

0.89 ± 0.36

0.88 ± 0.68

0.93

AFP (ng/mL)

3460.38 ± 14382.67

2449.96 ± 8.177.59

0.85

  1. AFP Alpha fetoprotein, ALT Alanine aminotransferase, AST Aspartate aminotransferase, INR International normalized ratio, mg/dL Milligram per deciliter; ng/mL, Nanogram per milliliter; SD Standard deviation, TACE Trans-arterial chemoembolization, U/L Units per liter, µL Microliter
  2. *p-value ≤ 0.05